Aetna Insurance Company Approves SpaceOAR With Radiation Therapy

Augmenix, Inc. has announced that Aetna, the third largest commercial health plan provider in the United States, has published an update to their Clinical Policy Bulletin 0926 which states that Aetna considers transperineal periprostatic placement of biodegradable material (SpaceOAR hydrogel) medically necessary for reducing rectal toxicity in men undergoing radiotherapy for prostate cancer. 

Joel T. Nowak, MA, MSW wrote this Post.  Joel is the CEO/Executive Director of Cancer ABCs.  He is a Cancer Thriver diagnosed with five primary cancers - Thyroid, Metastatic Prostate, Renal, Melanoma, and the rare cancer Appendiceal cancer.